Article ID Journal Published Year Pages File Type
9340823 Urologic Oncology: Seminars and Original Investigations 2005 5 Pages PDF
Abstract
The combination of GM-CSF + thalidomide is relatively well tolerated and has the potential to produce antitumor activity in a population of patients with metastatic, androgen independent prostate cancer. This nonchemotherapy combination should be explored in a subset of patients with less advanced disease.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Oncology
Preview
Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer
Authors
, , , , , ,